Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.

Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

On Thursday, Ionis Pharmaceuticals Inc (IONS) stock saw a decline, ending the day at $38.49 which represents a decrease of $-0.67 or -1.71% from the prior close of $39.16. The stock opened at $39.07 ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jason Gerberry, an analyst from Bank of America Securities, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report).